A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee

Osteoarthritis and Cartilage

Volumn 5, Issue 4, 1997, Pages 283-288

  Goei The, H S ^a   Lund, B ^a   Distel, M R ^a   Bluhmki, E ^a  

^a Sittard Geleen Heerlen   (Netherlands)

Author keywords

Diclofenac; Meloxicam; NSAIDs; Osteoarthritis

Indexed keywords

MELOXICAM;

ADULT; AGED; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0030876026     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(97)80024-6     Document Type: Article

References (16)

1. Dieppe PA Bacon PA Bamij AW Watt I Osteoarthritis Atlas of Clinical Rheumatology 1986 Gower Medical Publishing London
2. Roth SH Bennett RE Nonsteroidal anti-inflammatory drug gastropathy Arch Intern Med 147 1987 2093 2100
3. Larkai EN Smith JL Lidsky MD Graham DY Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use Am J Gastroenterol 82 1987 1153 1158
4. 14C-labelled meloxicam: a new antiphlogistic drug in man. [Abstract] XVIIth ILAR Congress of Rheumatology Rio de Janerio, September 1989
5. Engelhardt G Meloxicam: Comparison of in vitro and in vivo activity Rio de Janeiro, 17–23 September Presented at the XVIIth ILAR Congress of Rheumatology 179 1989 P191
6. Engelhardt G Meloxicam: a potent inhibitor of COX-2 Data presented at the International Conference on Prostaglandins and Related Compounds Florence, Italy, 6–10 June 1994 82
7. Brogden RN Heel RC Pakes GE Speight TM Avery GS Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin Drugs 20 1980 24 48
8. Laws D Saul S Fehilly B A microcomputer-assisted study of nabumetone and slow release diclofenac in osteoarthritis Drugs 40 1990 29 33
9. Schubinger BI Ciccolunghi SN Tanner K Once daily dose treatment with a non-steroidal anti-rheumatic drug (diclofenac) in osteoarthritis J Int Med Res 8 1980 167 174
10. Langman MJS Well J Wainwright P Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs Lancet 343 1994 1075 1078
11. (Suppl.) Lequesne MG Mery C Samson M Gerard P Indexes of severity ofosteoarthritis in the hip and knee Scand J Rheumatol 65 1987 85 89
12. Lund B Distel M Bluhmki E A double-blind placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee [Abstract] Scand J Rheumatol 23 Suppl. 98 1994 117
13. Lindén B Distel M Bluhmki E Double-blind randomised comparison of meloxicam and piroxicam in patients with osteoarthritis (OA) of the hip [Abstract] Scand J Rheumatol 23 Suppl. 98 1994 182
14. Distel M Mueller C Bluhmki E Fries J Safety of meloxicam: a global analysis of clinical trials Br J Rheumatol 35 Suppl. 1 1996 68 77
15. Engelhardt G Homma D Schlegel K Utzmann R Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with gastrointestinal tolerance Inflamm Res 44 1995 423 433
16. Vane J Towards a better aspirin Nature 367 1994 215 216